Log in

Relevant bibliographies by topics / TMPRSS2-ERG fusion / Journal articles

To see the other types of publications on this topic, follow the link: TMPRSS2-ERG fusion.

Journal articles on the topic 'TMPRSS2-ERG fusion'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'TMPRSS2-ERG fusion.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

He, Wei, Fukang Sun, Juping Zhao, et al. "Prevalence and genetic features of TMPRSS2-ERG fusion in Chinese patients with prostate cancer." Journal of Clinical Oncology 38, no. 15_suppl (2020): e17529-e17529. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e17529.

Full text

Abstract:

e17529 Background: Prostate cancer (PCa) is one of the most common malignancies, with rising incidence rate in China. The Cancer Genome Atlas (TCGA) revealed 53% of patients with PCa had ETS family gene fusions. The most frequent fusion type of ETS fusions is TMPRSS2-ERG, which may predicts resistance to taxane and androgen-deprivation therapies. The prevalence of TMPRSS2-ERG fusion in Chinese PCa patients evaluated by fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) varied from 7.5% to 78.0%. However, the sample sizes were small. In the present study, we investigated th

APA, Harvard, Vancouver, ISO, and other styles

2

Minner, S., A. Krohn, L. Burkhardt, et al. "Chromosomal deletions, tumor phenotype, and prognosis in prostate cancer." Journal of Clinical Oncology 29, no. 7_suppl (2011): 37. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.37.

Full text

Abstract:

37 Background: Chromosomal deletions are frequent in prostate cancer (PCa) but target genes and potential clinical significance are often unknown. This project aimed at the identification of frequent and new deletions in PCa and to study their association with tumor phenotype and PSA recurrence. Methods: Array CGH was performed on 77 advanced PCa. Deletions of interest were subsequently analyzed on a tissue microarray containing more than 2000 PCa with clinical follow-up data using fluorescence in situ hybridization (FISH). The FISH probes used included a break-apart probe for TMPRSS2-ERG and

APA, Harvard, Vancouver, ISO, and other styles

3

Yoshimoto, M., A. M. Joshua, S. Chilton-Macneill, et al. "Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer." Journal of Clinical Oncology 24, no. 18_suppl (2006): 10029. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10029.

Full text

Abstract:

10029 Background: Most of the early successes in identifying chromosomal translocations in neoplasias came from the study of hematological malignancies and sarcomas, with limited evidence that consistent genomic rearrangements were present in epithelial malignancies. Recently it was reported that ∼75% of prostate cancers carry a genomic rearrangement leading to fusion of the TMPRSS2 locus to either the ERG or ETV1 genes (both ETS transcription factors). In the fusion gene, the androgen-sensitive promoter elements of TMPRSS2 are thought to mediate over-expression of these ETS transcription fact

APA, Harvard, Vancouver, ISO, and other styles

4

Lara, Primo N., Andreas M. Heilmann, Julia A. Elvin, et al. "TMPRSS2-ERG Fusions Unexpectedly Identified in Men Initially Diagnosed With Nonprostatic Malignancies." JCO Precision Oncology, no. 1 (November 2017): 1–6. http://dx.doi.org/10.1200/po.17.00065.

Full text

Abstract:

Purpose TMPRSS2-ERG gene fusions are frequently found in prostate cancer and are pathognomonic for prostatic origin. In a series of cancer cases assayed with comprehensive genomic profiling (CGP) in the course of clinical care, we reviewed the frequency of TMPRSS2-ERG fusions in patient tumors of various histologic subtypes. Methods Frequency of TMPRSS2-ERG fusions was determined in CGPs from 64,263 cancer cases submitted to Foundation Medicine to assess genomic alterations suggesting benefit from targeted therapy. Genomic results are presented from an index case of prostate cancer that underw

APA, Harvard, Vancouver, ISO, and other styles

5

Mani, Ram-Shankar, Scott A. Tomlins, Kaitlin Callahan, et al. "Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer." Science 326, no. 5957 (2009): 1230. http://dx.doi.org/10.1126/science.1178124.

Full text

Abstract:

Gene fusions play a critical role in cancer progression. The mechanisms underlying their genesis and cell type specificity are not well understood. About 50% of human prostate cancers display a gene fusion involving the 5′ untranslated region of TMPRSS2, an androgen-regulated gene, and the protein-coding sequences of ERG, which encodes an erythroblast transformation–specific (ETS) transcription factor. By studying human prostate cancer cells with fluorescence in situ hybridization, we show that androgen signaling induces proximity of the TMPRSS2 and ERG genomic loci, both located on chromosome

APA, Harvard, Vancouver, ISO, and other styles

6

Dal Pra, Alan, Fiona Warde, Adrian Shea Ishkanian, et al. "TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer." Journal of Clinical Oncology 30, no. 5_suppl (2012): 11. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.11.

Full text

Abstract:

11 Background: Approximately 50% of prostate cancers (PC) contain TMPRSS2-ERG gene fusions leading to ERG overexpression. Pre-clinical data suggest that these fusions are due to altered DNA double-strand break repair status which could have therapeutic ramification for the use of radiotherapy (RT) and PARP inhibitors. The aim of this study was to correlate TMPRSS2-ERG status to biochemical failure following clinical induction of DNA breaks in the form of image-guided radiotherapy (IGRT) in intermediate-risk PC. Methods: Pre-treatment biopsies from two separate cohorts of intermediate-risk PC p

APA, Harvard, Vancouver, ISO, and other styles

7

Sung, Ji-Youn, Hwang Gyun Jeon, Byong Chang Jeong, et al. "Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion." Journal of Clinical Pathology 69, no. 7 (2015): 586–92. http://dx.doi.org/10.1136/jclinpath-2015-203314.

Full text

Abstract:

AimsTMPRSS2/E26 transformation-specific (ETS) family gene fusion in prostate carcinoma (PCa) can be detected by several methods including immunohistochemistry (IHC) for ETS-related gene (ERG), the diagnostic utility of which has not been clearly defined.MethodsWe explored TMPRSS2-ERG gene rearrangement status in 132 patients with PCa with four detection methods including fluorescence in situ hybridisation for TMPRSS2-ERG fusion, real-time reverse transcription PCR (RT-qPCR) for ERG and TMPRSS-ERG fusion transcript mRNA and IHC for ERG.ResultsConcordant results were found in 126 cases for the f

APA, Harvard, Vancouver, ISO, and other styles

8

Graff, Rebecca E., Allison Meisner, Thomas Ahearn, et al. "Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by TMPRSS2:ERG status." Journal of Clinical Oncology 34, no. 2_suppl (2016): 93. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.93.

Full text

Abstract:

93 Background: Experimental studies have shown that androgen receptor stimulation can facilitate formation of the TMPRSS2:ERG gene fusion in prostate cell lines. No study has tested whether higher pre-diagnostic circulating sex hormone levels in men increase the risk of developing TMPRSS2:ERG positive prostate cancer specifically. Methods: We conducted a nested case-control study of 200 prostate cancer cases and 1,057 controls from the Physicians’ Health Study and Health Professionals Follow-up Study. We examined associations between pre-diagnostic circulating levels of total testosterone, fre

APA, Harvard, Vancouver, ISO, and other styles

9

KULDA, VLASTIMIL, ONDREJ TOPOLCAN, RADEK KUCERA, et al. "Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer." Anticancer Research 36, no. 9 (2016): 4787–94. http://dx.doi.org/10.21873/anticanres.11037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Knuuttila, Matias, Arfa Mehmood, Jenni Mäki-Jouppila, et al. "Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer." Endocrine-Related Cancer 25, no. 9 (2018): 807–19. http://dx.doi.org/10.1530/erc-18-0148.

Full text

Abstract:

Intratumoral androgen biosynthesis is one of the mechanisms involved in the progression of prostate cancer, and an important target for novel prostate cancer therapies. Using gas chromatography-tandem mass spectrometry and genome-wide RNA sequencing, we have analyzed androgen concentrations and androgen-regulated gene expression in cancerous and morphologically benign prostate tissue specimens and serum samples obtained from 48 primary prostate cancer patients. Intratumoral dihydrotestosterone (DHT) concentrations were significantly higher in the cancerous tissues compared to benign prostate (

APA, Harvard, Vancouver, ISO, and other styles

11

Mao, Xueying, Nuria Coll Bastus, Lara Boyd, et al. "The different genetic alterations between Western and Chinese prostate cancers and the underlying mechanisms." Journal of Clinical Oncology 30, no. 5_suppl (2012): 184. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.184.

Full text

Abstract:

184 Background: Prostate cancer shows a wide variation in the clinical incidence and mortality rates of different geographical regions. While it is the most common male cancer in Western countries, it is much less frequent in Asian countries. We investigated genomic changes in prostate cancers from UK and China using microarrays to determine the genetic similarities and differences as well as the underlying mechanisms. Methods: We determined genome-wide genomic alterations using Affymetrix SNP array 6.0, and evaluated data using fluorescence in situ hybridisation (FISH) and immunohistochemistr

APA, Harvard, Vancouver, ISO, and other styles

12

Klein, E. A., S. M. Falzarano, T. Maddala, et al. "Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy." Journal of Clinical Oncology 29, no. 7_suppl (2011): 36. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.36.

Full text

Abstract:

36 Background: The association of TMPRSS2-ERG fusions and ERG expression in prostate cancer (PC) with adverse clinical outcomes has been controversial, with mixed results in the literature. We conducted a study to test whether tumor-derived gene expression profiles, including the presence of TMPRSS2-ERG fusions and ERG gene expression, are associated with clinical recurrence (cR) after radical prostatectomy (RP). Methods: All patients with clinical stage T1/T2 prostate cancer treated with RP at CC from 1987 to 2004 were identified (n∼f2,600). A cohort sampling design was used to select 127 pat

APA, Harvard, Vancouver, ISO, and other styles

13

Giunchi, Francesca, Francesco Massari, Annalisa Altimari, et al. "Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers." Diagnostics 10, no. 12 (2020): 1109. http://dx.doi.org/10.3390/diagnostics10121109.

Full text

Abstract:

The TMPRSS2:ERG fusion is considered prostate specific and has been rarely described in other tumors. We describe the case of a patient who developed lung and prostate cancers, both harboring the TMPRSS2:ERG fusion. The patient developed a cancer of the prostate with lymph node metastases and after two years a nodule of the thoracic wall. The histology and immunohistochemical profile of the two tumors were typical of prostate and lung cancers. The presence of the TMPRSS2:ERG fusion was demonstrated by next-generation sequencing on both malignancies, leading to the assumption that the lung nodu

APA, Harvard, Vancouver, ISO, and other styles

14

Washington, Michele N., та Nancy L. Weigel. "1α,25-Dihydroxyvitamin D3 Inhibits Growth of VCaP Prostate Cancer Cells Despite Inducing the Growth-Promoting TMPRSS2:ERG Gene Fusion". Endocrinology 151, № 4 (2010): 1409–17. http://dx.doi.org/10.1210/en.2009-0991.

Full text

Abstract:

Vitamin D receptor (VDR) agonists have been shown to reduce the growth of several prostate cancer cell lines. However, the effects of VDR activation have not been examined in the presence of the recently identified androgen-regulated TMPRSS2:ERG gene fusions, which occur in a high percentage of prostate cancers and play a role in growth and invasiveness. In a previous microarray study, we found that VDR activation induces TMPRSS2 expression in LNCaP prostate cancer cells. Here we show that the natural VDR agonist 1α,25-dihydroxyvitamin D3 and its synthetic analog EB1089 increase expression of

APA, Harvard, Vancouver, ISO, and other styles

15

Gerashchenko, G. V., L. V. Mevs, L. I. Chashchina, et al. "EXPRESSION OF STEROID AND PEPTIDE HORMONE RECEPTORS, METABOLIC ENZYMES AND EMT-RELATED GENES IN PROSTATE TUMORS IN RELATION TO THE PRESENCE OF THE TMPRSS2/ERG FUSION." Experimental Oncology 40, no. 2 (2018): 101–8. http://dx.doi.org/10.31768/2312-8852.2018.40(2):101-108.

Full text

Abstract:

Aim: To analyze an expression pattern of the steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion; and to examine a putative correlation between gene expression and clinical characteristics, to define the molecular subtypes of prostate cancer. Materials and Methods: The relative gene expression (RE) of 33 transcripts (27 genes) and the presence/absence of the TMPRSS2/ERG fusion were analyzed by a quantitative PCR. 37 prostate cancer tissues (T) paired with conventionally normal prostate tissue (C

APA, Harvard, Vancouver, ISO, and other styles

16

Clark, Jarrod P., Kristofer W. Munson, Jessie W. Gu, et al. "Performance of a Single Assay for Both Type III and Type VI TMPRSS2:ERG Fusions in Noninvasive Prediction of Prostate Biopsy Outcome." Clinical Chemistry 54, no. 12 (2008): 2007–17. http://dx.doi.org/10.1373/clinchem.2008.108845.

Full text

Abstract:

Abstract Background: TMPRSS2:ERG fusions are promising prostate cancer biomarkers. Because they can occur in multiple forms in a single cancer specimen, we developed a quantitative PCR test that detects both type III and type VI TMPRSS2:ERG fusions. The assay is quantified from a standard curve determined with a plasmid-cloned type III TMPRSS2:ERG fusion target. Methods: We collected expressed prostatic secretion (EPS) under an institutional review board-approved, blinded, prospective study from 74 patients undergoing transrectal ultrasound-guided biopsy for prostate cancer. We compared the ch

APA, Harvard, Vancouver, ISO, and other styles

17

Gasi Tandefelt, Delila, Joost Boormans, Karin Hermans, and Jan Trapman. "ETS fusion genes in prostate cancer." Endocrine-Related Cancer 21, no. 3 (2014): R143—R152. http://dx.doi.org/10.1530/erc-13-0390.

Full text

Abstract:

Prostate cancer is very common in elderly men in developed countries. Unravelling the molecular and biological processes that contribute to tumor development and progressive growth, including its heterogeneity, is a challenging task. The fusion of the genes ERG and TMPRSS2 is the most frequent genomic alteration in prostate cancer. ERG is an oncogene that encodes a member of the family of ETS transcription factors. At lower frequency, other members of this gene family are also rearranged and overexpressed in prostate cancer. TMPRSS2 is an androgen-regulated gene that is preferentially expresse

APA, Harvard, Vancouver, ISO, and other styles

18

Trifunovski, Aleksandar, Aleksandar Dimovski, Sasho Dohcev, et al. "Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience." PRILOZI 41, no. 1 (2020): 5–14. http://dx.doi.org/10.2478/prilozi-2020-0018.

Full text

Abstract:

AbstractIntroduction: Prostate carcinoma is the most frequent malign neoplasm among men with an ever-growing incidence rate. TMPRSS2-ERG fusion transcript leads to the androgen induction of ERG proto-oncogenes expression, representing a high presence of oncogenes alteration among prostate tumour cells.Aim: The aim of this research was to detect and evaluate theTMPRSS2-ERG fuse transcript in the tissues of patients with prostate cancer, and establish a base of material of these samples for further genetic examination.Materials and methods: The research was a prospective clinical study that invo

APA, Harvard, Vancouver, ISO, and other styles

19

Russo, Leileata M., Kendall Bate, Piruz Motamedinia, et al. "Urinary exosomes as a stable source of mRNA for prostate cancer analysis." Journal of Clinical Oncology 30, no. 5_suppl (2012): 174. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.174.

Full text

Abstract:

174 Background: Exosomes are novel lipid bilayer vesicles that are released into biofluids such as urine and carry high integrity RNA from the parent cell which they were derived. Due to their unique stability and the fact that they contain prostate specific mRNA transcripts, we examined their potential as a non-invasive source of mRNA biomarkers for prostate cancer analysis. Methods: Following a Columbia University approved IRB protocol, random urine samples were collected from 163 men who were stratified into 4 groups: biopsy negative (Bx Neg, n=39), biopsy positive (Bx Pos, n=47), post-radi

APA, Harvard, Vancouver, ISO, and other styles

20

Burdova, Alena, Jan Bouchal, Spiros Tavandzis, and Zdenek Kolar. "TMPRSS2-ERG gene fusion in prostate cancer." Biomedical Papers 158, no. 4 (2014): 502–10. http://dx.doi.org/10.5507/bp.2014.065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Lu, Yong-Jie, Xiaoyan Liu, Xueying Mao, et al. "Truncation of BRAF and Raf1 in prostate cancer in China." Journal of Clinical Oncology 30, no. 5_suppl (2012): 77. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.77.

Full text

Abstract:

77 Background: Chromosome translocations and fusion genes have been identified as common events in carcinomas in recent years and TMPRSS2:ERG fusions have been found in about half of human prostate cancers. However, by genome-wide analysis of Chinese prostate cancer cases, we found that certain genomic alterations, commonly identified in prostate cancer samples from the Western countries, occurred at a very low frequency in China, including the fusion of TMPRSS2:ERG. In 2010, recurrent fusion genes involving the RAF family gene BRAF and Raf1 were identified (Palanisamy et al, Nature Med. 16:79

APA, Harvard, Vancouver, ISO, and other styles

22

Grande, Enrique, Maria Piedad Fernandez Perez, Daniel Wetterskog, et al. "A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): 5040. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5040.

Full text

Abstract:

5040 Background: TMPRSS2-ERG fusion gene is a common driver of prostate cancer. The PREMIERE study is a phase II, single arm open-label, multicentre, clinical trial designed to analyse the predictive/prognostic value of TMPRSS2-ERG in first-line chemo-naïve mCRPC patients treated with enzalutamide. Methods: We centrally evaluated TMPRSS2-ERG in diagnostic samples using PCR, FISH and IHC for ERG. Among exploratory biomarkers we included plasma DNA, AR copy number by ddPCR and CTC by AdnaTest. PCWG2 criteria were used for outcome evaluation. We correlated TMPRSS2-ERGand other exploratory biomark

APA, Harvard, Vancouver, ISO, and other styles

23

Deplus, Rachel, Carine Delliaux, Nathalie Marchand, et al. "TMPRSS2-ERG fusion promotes prostate cancer metastases in bone." Oncotarget 8, no. 7 (2016): 11827–40. http://dx.doi.org/10.18632/oncotarget.14399.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bismar, Tarek A., and Kiril Trpkov. "TMPRSS2-ERG gene fusion in transition zone prostate cancer." Modern Pathology 23, no. 7 (2010): 1040–41. http://dx.doi.org/10.1038/modpathol.2010.89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

SABALIAUSKAITĖ, Rasa, Donatas PETROŠKA, Darius DASEVIČIUS, et al. "Molecular analysis of multifocal prostate cancer cases." Acta medica Lituanica 18, no. 4 (2011): 147–55. http://dx.doi.org/10.6001/actamedica.v18i4.1867.

Full text

Abstract:

Background. Prostate cancer (PCa) is usually a multifocal disease with different foci displaying histological and molecular heterogeneity. Biopsy-based pathology diagnosis of PCa may not be representative of the entire tumour; thus, markers more precisely characterizing every focus of multifocal PCa are highly instrumental for a better testing of PCa. Materials and Methods. Two distant foci of prostate adenocarcinoma were obtained from prostatectomy specimens of ten patients with pT2–pT3 stage PCa. The expression of TMPRSS2 : ERG, TMPRSS2 : ETV1, and TERT was assessed by means of reverse trans

APA, Harvard, Vancouver, ISO, and other styles

26

Fasulo, Vittorio, Massimo Lazzeri, Marinella Corbetta, et al. "TMPRSS2: ERG expression in prostate cancer—Imaging and clinicopathological correlations." Journal of Clinical Oncology 38, no. 6_suppl (2020): 284. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.284.

Full text

Abstract:

284 Background: The TMPRSS2:ERG gene fusion (T:E) is found in up to 70% of prostate cancers (PCa) and results in androgen dependent overexpression of ERG, promoting tumor growth. The early identification of T:E may be helpful even in low-risk PCa. Although T:E can be non-invasively detected in urine, its correlation with new imaging tools (MRI and high-frequency ultrasound) and clinical outcome remains vague.This study investigates T:E expression in patients scheduled for random/software-assisted MRI or micro-ultrasound (29Mhz) fusion biopsy. Methods: This is a prospective cohort study in pati

APA, Harvard, Vancouver, ISO, and other styles

27

Krumbholz, Manuela, Abbas Agaimy, Robert Stoehr, et al. "Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer." Disease Markers 2019 (December 12, 2019): 1–8. http://dx.doi.org/10.1155/2019/5085373.

Full text

Abstract:

There is increasing interest in the use of cell-free circulating tumor DNA (ctDNA) as a serum marker for therapy assessment in prostate cancer patients. Prostate cancer is characterized by relatively low numbers of mutations, and, in contrast to many other common epithelial cancers, commercially available single nucleotide mutation assays for quantification of ctDNA are insufficient for therapy assessment in this disease. However, prostate cancer shares some similarity with translocation-affected mesenchymal tumors (e.g., leukemia and Ewing sarcoma), which are common in pediatric oncology, whe

APA, Harvard, Vancouver, ISO, and other styles

28

Mucci, Lorelei A., Thomas Ahearn, Kathryn Penney, et al. "Precision prevention of TMPRSS2:ERG prostate cancer." Journal of Clinical Oncology 34, no. 2_suppl (2016): 78. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.78.

Full text

Abstract:

78 Background: Increased integration of tumor biomarker data into prostate cancer epidemiology studies is needed to identify molecular subtypes that underlie its etiology and progression. We hypothesize that the TMPRSS2:ERG gene fusion is a unique prostate cancer subtype that is etiologically distinct from cancers lacking TMPRSS2:ERG. Methods: We leveraged the Physicians’ Health Study and Health Professionals Follow-up Study cohort data on pre- and post-diagnostic lifestyle factors, inherited genetic variants, circulating biomarkers, and clinical data and follow-up for 30 years. We have a tumo

APA, Harvard, Vancouver, ISO, and other styles

29

Mwamukonda, K., Y. Chen, L. Ravindranath, et al. "Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2–ERG fusion status." Prostate Cancer and Prostatic Diseases 13, no. 1 (2009): 47–51. http://dx.doi.org/10.1038/pcan.2009.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Niraula, S., U. Emmeneger, L. Adams, et al. "Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology." Journal of Clinical Oncology 29, no. 7_suppl (2011): 59. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.59.

Full text

Abstract:

59 Background: Other than the androgen receptor, the TMPRSS2-ERG genomic aberrations in prostate cancer provide the first recent opportunity to target therapy in castration refractory prostate cancer (CRPC). We initiated a phase II clinical trial of cytarabine in docetaxel refractory CRPC on the basis of microarray, in vitro and case report evidence that cytarabine may be particularly effective in men harbouring abnormalities of the ERG oncogenes. Embedded in this clinical trial was the first use of blood mRNA levels of prostate cancer related genes as biomarkers of response and prognosis. Met

APA, Harvard, Vancouver, ISO, and other styles

31

Gupta, Sachin Kumar, Liming Luo, and Laising Yen. "RNA-mediated gene fusion in mammalian cells." Proceedings of the National Academy of Sciences 115, no. 52 (2018): E12295—E12304. http://dx.doi.org/10.1073/pnas.1814704115.

Full text

Abstract:

One of the hallmarks of cancer is the formation of oncogenic fusion genes as a result of chromosomal translocations. Fusion genes are presumed to form before fusion RNA expression. However, studies have reported the presence of fusion RNAs in individuals who were negative for chromosomal translocations. These observations give rise to “the cart before the horse” hypothesis, in which the genesis of a fusion RNA precedes the fusion gene. The fusion RNA then guides the genomic rearrangements that ultimately result in a gene fusion. However, RNA-mediated genomic rearrangements in mammalian cells h

APA, Harvard, Vancouver, ISO, and other styles

32

Wang, Zhu, Yuliang Wang, Jianwen Zhang, et al. "Significance of the TMPRSS2:ERG gene fusion in prostate cancer." Molecular Medicine Reports 16, no. 4 (2017): 5450–58. http://dx.doi.org/10.3892/mmr.2017.7281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Tomlins, Scott A., Bharathi Laxman, Sooryanarayana Varambally, et al. "Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer." Neoplasia 10, no. 2 (2008): 177—IN9. http://dx.doi.org/10.1593/neo.07822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Brooks, James. "Role of the TMPRSS2-ERG gene fusion in prostate cancer." Urologic Oncology: Seminars and Original Investigations 26, no. 5 (2008): 569. http://dx.doi.org/10.1016/j.urolonc.2008.07.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Cheng, Liang, Darrell D. Davidson, Gregory T. MacLennan, et al. "Atypical Adenomatous Hyperplasia of Prostate Lacks TMPRSS2-ERG Gene Fusion." American Journal of Surgical Pathology 37, no. 10 (2013): 1550–54. http://dx.doi.org/10.1097/pas.0b013e318294e9bc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Albadine, Roula, Mathieu Latour, Antoun Toubaji, et al. "TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma." Modern Pathology 22, no. 11 (2009): 1415–22. http://dx.doi.org/10.1038/modpathol.2009.121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Stone, Louise. "Stuck in the middle: interstitial genes in TMPRSS2–ERG fusion." Nature Reviews Urology 15, no. 1 (2017): 3. http://dx.doi.org/10.1038/nrurol.2017.208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Clark, J., S. Merson, S. Jhavar, et al. "Diversity of TMPRSS2-ERG fusion transcripts in the human prostate." Oncogene 26, no. 18 (2006): 2667–73. http://dx.doi.org/10.1038/sj.onc.1210070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Bastus, Nuria Coll, Lara K. Boyd, Xueying Mao, et al. "Androgen-Induced TMPRSS2:ERG Fusion in Nonmalignant Prostate Epithelial Cells." Cancer Research 70, no. 23 (2010): 9544–48. http://dx.doi.org/10.1158/0008-5472.can-10-1638.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Adra, Nabil, Liang Cheng, Nasser H. Hanna, and Greg Durm. "TMPRSS2-ERG Fusion in an Uncommon Presentation of Prostate Cancer." Clinical Genitourinary Cancer 15, no. 3 (2017): e489-e491. http://dx.doi.org/10.1016/j.clgc.2017.01.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Velaeti, S., E. Dimitriadis, K. Kontogianni-Katsarou, et al. "Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia." Tumor Biology 35, no. 10 (2014): 9597–602. http://dx.doi.org/10.1007/s13277-014-2250-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Schmidt, Folke, Kirsten Mertz, Sven Perner, et al. "ERG EXPRESSION VARIES IN DIFFERENT ISOFORMS OF TMPRSS2:ERG GENE FUSION IN PROSTATE CANCER." Journal of Urology 179, no. 4S (2008): 393. http://dx.doi.org/10.1016/s0022-5347(08)61150-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Wang, Shiyuan, Qi Zhang, Dandan Xu, et al. "Characterize the difference between TMPRSS2-ERG and non-TMPRSS2-ERG fusion patients by clinical and biological characteristics in prostate cancer." Gene 679 (December 2018): 186–94. http://dx.doi.org/10.1016/j.gene.2018.09.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Chaux, Alcides, Roula Albadine, Antoun Toubaji, et al. "Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas." American Journal of Surgical Pathology 35, no. 7 (2011): 1014–20. http://dx.doi.org/10.1097/pas.0b013e31821e8761.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Kobelyatskaya, Anastasiya A., Elena A. Pudova, Anastasiya V. Snezhkina, et al. "Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence." Life 11, no. 6 (2021): 588. http://dx.doi.org/10.3390/life11060588.

Full text

Abstract:

Currently, seven molecular subtypes of prostate cancer (PCa) are known, the most common of which being the subtype characterized by the presence of the TMPRSS2–ERG fusion transcript. While there is a considerable amount of work devoted to the influence of this transcript on the prognosis of the disease, data on its role in the progression and prognosis of PCa remain controversial. The present study is devoted to the analysis of the association between the TMPRSS2–ERG transcript and the biochemical recurrence of PCa. The study included two cohorts: the RNA–Seq sample of Russian patients with PC

APA, Harvard, Vancouver, ISO, and other styles

46

Soller, W., M. Johansson Soller, M. Isaksson, et al. "HIGH FREQUENCY OF THE TMPRSS2/ERG FUSION GENE IN PROSTATE CANCER." European Urology Supplements 5, no. 14 (2006): 789. http://dx.doi.org/10.1016/s1569-9056(06)61261-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kalogeropoulos, T., S. Velaeti, E. Dimitriadis, et al. "355 DETECTION OF TMPRSS2-ERG FUSION GENES IN PROSTATE BENIGN HYPERPLASIA." European Urology Supplements 8, no. 4 (2009): 209. http://dx.doi.org/10.1016/s1569-9056(09)60358-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Salagierski, Maciej, and Jack A. Schalken. "Molecular Diagnosis of Prostate Cancer: PCA3 and TMPRSS2:ERG Gene Fusion." Journal of Urology 187, no. 3 (2012): 795–801. http://dx.doi.org/10.1016/j.juro.2011.10.133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Velaeti, S., T. Kalogeropoulos, T. Karaolidis, et al. "S21 Detection of TMPRSS2-ERG fusion gene in benign prostate hyperplasia." European Urology Supplements 8, no. 8 (2009): 614. http://dx.doi.org/10.1016/s1569-9056(09)74902-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Gao, Chunling, Bungo Furusato, David G. McLeod, Shiv Srivastava, Gyorgy Petrovics, and Isabell A. Sesterhenn. "1125: Mapping of TMPRSS2-ERG Fusion in Multi-Focal Prostate Cancer." Journal of Urology 177, no. 4S (2007): 371–72. http://dx.doi.org/10.1016/s0022-5347(18)31339-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!